Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

nageable. Triglycerides and cholesterol were not elevated and had no negative impact on the cardiovascular safety profile. Hair growth (hirsutism) was observed in 5% of patients. Otherwise the safety profile was similar to placebo.

  • In study LX211-01 the 0.4 mg/kg BID dose fully met the primary endpoint of superiority to placebo at both weeks 16 (p=0.008) and week 24 (p=0.027) for mean change from baseline in vitreous haze, a validated measure of inflammation of the posterior segment of the eye. The magnitude of the effect was >1 step change from baseline, demonstrating a clinically relevant benefit.

  • In study LX211-02 the 0.4 mg/kg BID dose showed a reduction by 50% vs. placebo in rate of recurrence of inflammation at 6 months using a pre-specified analysis that accounted for data censoring due to non-efficacy-related discontinuations. This reduction was statistically significant (p=0.045), thus confirming the positive results from LX211-01.

  • In study LX211-03, treated patients reduced the cellular response in the front of the eye from an average of more than 25 white blood cells per high power microscopic field to an average of 6 to 10 cells per high power field. However, placebo-treated patients also improved in this study and it was therefore not possible to show that LX211 was effective for this rare subset of uveitis patients, those with refractory disease in the anterior portion of the eye.

    The LUMINATE program was conducted under the sponsorship of Lux Biosciences.


    '/>"/>

  • Contact: Joan Kureczka
    JKureczka@comcast.net
    415-821-2413
    Kureczka/Martin Associates
    Source:Eurekalert

    Page: 1 2 3 4

    Related biology technology :

    1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
    2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
    3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
    4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
    5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
    6. The first DFG research centers to be funded for another 4 years
    7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
    8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
    9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
    10. United Therapeutics Reports First Quarter 2009 Financial Results
    11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
    (Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
    (Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
    (Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
    Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
    ... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
    ... BioSpace added Kansas to its annual promotional campaign of biotechnological, ... , , ... , , (Logo:   ... The leading employment Web site for the ...
    ... , July 29 Omeros Corporation (Nasdaq: ... equity financing facility under which it may sell up to ... to Azimuth Opportunity, Ltd. (the "investor") over a 24-month period. ... free to enter into and consummate other equity, debt and ...
    Cached Biology Technology:Empa grows 'sea urchin'-shaped structures 2BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4
    (Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
    (Date:7/10/2014)... The yellow crazy ant Anoplolepis gracilipes is ranked ... responsible for catastrophic ecological impacts on islands. A new study ... examines and assesses the effects and dangers of the ... of the mature palm forest of the Valle de Mai, ... palm forest of Valle de Mai is a unique ecosystem ...
    (Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
    Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
    ... of proteins and other chemicals that underlies most ... molecules that accelerate chemical reactions between molecules. The ... the synthesis of chemicals and pharmaceuticals, devise new ... therapies. In the August 16 issue of ...
    ... has journeyed to this section of Antarcticas Amundsen Sea, but ... researchers and a Boerne High School science teacher will join ... sail on a two month expedition. The trip, ... to UTSA, is designed to study the relationship of sea ...
    ... evidence reported in the August issue of Cell Stem Cell, ... how the HIV/AIDS virus leads to learning and memory deficits, ... the surface of the virus not only kills some mature ... prevents the birth of new brain cells by crippling adult ...
    Cached Biology News:MGH researchers describe new way to identify, evolve novel enzymes 2Texas researchers and educators head for Antarctica 2HIV is a 'double hit' to the brain 2
    ... This 2500ml narrow mouth PYREX low form culture flask ... area to volume ratio. This flask has a heavy ... large marking spot. The neck O.D. is 38mm and ... not use this flask on a heat source smaller ...
    ... to achieve in many bacterial strains due ... restriction and modification (R-M) systems that cleave ... TypeOne™ Restriction Inhibitor provides a powerful method ... with type I R-M systems. Developed ...
    ... cassette is designed to allow ... The prokaryotic promoter gb2 driving the ... slightly modified version of the Em7 ... than the generally used Tn5 promoter. ...
    Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
    Biology Products: